JNJ-64565111 evaluated for safety and efficacy in non-diabetic severely obese participants

Obesity is a complex, chronic disease characterized by excessive body fat accumulation, significantly increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Despite lifestyle interventions, many individuals struggle to achieve and maintain clinically meaningful weight loss. Current pharmacotherapies, while effective for some, often have limitations in terms of efficacy, side effects, or long-term adherence. There remains a critical need for novel, safe, and highly effective therapeutic options to address the global obesity epidemic and improve patient outcomes. This study aims to explore JNJ-64565111 as a potential new treatment.

This randomized, placebo-controlled study is designed to evaluate JNJ-64565111 in non-diabetic severely obese participants. The primary objective is to assess the percent change in body weight from baseline after 26 weeks of treatment. Participants will be randomized to receive either JNJ-64565111 or placebo. Secondary objectives include evaluating the safety and tolerability profile of the compound. This design allows for a direct comparison of the investigational compound's effects against an inactive control in a well-defined patient population.

This record describes the purpose and design of a clinical trial, not its completed results. Therefore, no findings regarding the efficacy or safety of JNJ-64565111 are available at this time. The study aims to collect data on body weight reduction and adverse events over 26 weeks. Specific outcomes, including statistical significance or effect sizes, will be reported upon the study's completion and data analysis.